middle.news
Control Bionics Eyes Record FY25 Revenue as NeuroStrip® Trials Expand Globally
8:29am on Friday 13th of June, 2025 AEST
•
Healthcare
Read Story
Control Bionics Eyes Record FY25 Revenue as NeuroStrip® Trials Expand Globally
8:29am on Friday 13th of June, 2025 AEST
Key Points
FY25 revenue up 14% year-to-date, nearing $5.4 million
US sales boosted by new HCPCS insurance reimbursement code
Improved NDIS approvals enhance Australian market access
NeuroStrip® hardware trials underway in US, Japan, and Australia
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Control Bionics (ASX:CBL)
OPEN ARTICLE